Abuse can cause serious heart and psychological side effects. Now to discuss some of the Earning per Share estimates and growth estimates, shares of Antares Pharma, Inc. (NASDAQ:ATRS) produced diluted EPS of 0.03. Your email address will not be shared without your permission. Antares Pharma, Inc. 27 November 2019. Contact your organization’s admin about adding this content to your AdisInsight subscription. It does not require or replace the individual login accounts that many of you use to save searches and create email alerts. ... Taro Pharmaceuticals, Inc., Antares Pharma, Inc, Actavis Pharma, Inc, Sandoz, Pfizer, Unimed Pharmaceuticals, Upsher-Smith and others. Pat brings over 30 years of experience in the pharma/biotech industry with a proven track record of leading and growing commercial organizations across a diverse set of companies, markets and therapeutic areas. The insider ownership for the shares of Antares Pharma, Inc. (NASDAQ:ATRS) is ticked at 2.8%, the figure is rose 0.36% in the last six months. Adis International Ltd. Part of We need some information from you before you start using the platform. XYOSTED™ is the first FDA approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot® auto injector. No fluff and got straight to the point. Antares Pharma, Inc. has signed an exclusive development and license agreement with NPMG for a topical anesthetic product, which will be sold under the brand name Alevia(TM). Privacy Policy, Disclaimer, General Terms & Conditions. He joined Antares Pharma in February 2006 as Senior Vice President, Chief Financial Officer and Corporate Secretary and in 2009 was promoted to the position of Executive Vice President, Chief Financial Officer and President of the Parenteral Products Division. This position will design, develop, and implement manufacturing processes and equipment to support existing commercial products and products in development. 05 Nov 2020 Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results Read More. We would love to hear your thoughts or feedback on how we can improve your experience! Antares Pharma, Inc. (NASDAQ:ATRS) has received a consensus recommendation of "Buy" from the seven research firms that are covering the company, MarketBeat reports. The outstanding shares of Antares Pharma, Inc. (NASDAQ:ATRS) are 165.7 Million. You need to be a logged in subscriber to view this content. Antares Pharma has 178 employees across 2 locations and $123.86 M in annual revenue in FY 2019. But it is future earnings, more than anything, that will determine Antares Pharma's ability to maintain a … Please click the button to participate in our quick survey. I had a phone interview and one face to face, then a job offer. The institutional Ownership of the shares of 43.1 stands at 0.80%, this figure is decreased -5.7 in the last six months. Find the latest Antares Pharma, Inc. (ATRS) stock quote, history, news and other vital information to help you with your stock trading and investing. The P/S or Price to Sales ratio of Antares Pharma, Inc. (NASDAQ:ATRS) stands at 3.69 and Price to Book or P/B for the most recent quarter stands at 8.97. -Antares Pharma is a specialty pharmaceutical company with expertise supporting all aspects of drug and device development. Persisted access using your organization’s identifier stored in your user browser for 90 days. The company has a market capitalization of $508.24 Million. Testosterone can be abused, when taken at higher than prescribed doses and when used with other anabolic androgenic steroids. More Details. 10 Nov 2020 Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference Read More. Head to Head Stocks: Antares Pharma, Inc. (NASDAQ:ATRS), Attunity Ltd. (NASDAQ:ATTU), Face to Face Hot Stocks: Xcel Energy Inc. (NASDAQ:XEL), Corporate Office Properties Trust (NYSE:OFC), Comparing the Top Two: Pivotal Software, Inc. (NYSE:PVTL), Stag Industrial, Inc. (NYSE:STAG), Hot Versus Hot: Agile Therapeutics, Inc. (NASDAQ:AGRX), Auris Medical Holding AG (NASDAQ:EARS), Top Versus Top: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), UnitedHealth Group Incorporated (NYSE:UNH). A high-level overview of Antares Pharma, Inc. (ATRS) stock. The U.S. Food and Drug Administration on Monday approved Antares Pharma Inc's injectable drug to treat low testosterone levels in men, the company said, nearly a year after being rejected. Interview. The 52 week high of Antares Pharma, Inc. (NASDAQ:ATRS) is placed at 5.13 and 52 week low is standing at 1.60. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Antares Pharma, Inc. (NASDAQ:ATRS) stands at 4.2, 10.6 and 1 respectively. The company develops needle-free systems for administering injectable drugs. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. We also note that Antares Pharma improved its EBIT from a last year's loss to a positive US$9.2m. The number of times you access AdisInsight, the number of searches you performed, and the number of profiles you viewed will be provided to your organization both in aggregate with other users and individually by your email address. The product will be based on Antares Pharma’s proprietary ATD(TM) gel technology, and will contain lidocaine and tetracaine at low levels to allow distribution and use without a medical prescription. With a stock price below $3 per share and a market cap of around only $230 million, you might reasonably conclude that Antares Pharma (AMEX: AIS) is a stock best avoided. Trading at 73.2% below our estimate of its fair value. EWING, N.J., November 29, 2018 — Antares Pharma, Inc. (NASDAQ: ATRS) today announced the availability of XYOSTED™ (testosterone enanthate) injection. has a subscription Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Antares Pharma against related stocks people have also bought. Antares Pharma, Inc. (NASDAQ:ATRS) closed at $3.14 on the last trading session with an increase of 0.64%, whereas, it previously closed at $3.12. Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and … Antares Pharma has a robust pipeline of drug/device combination products including pen devices and auto injectors for self administration which are designed to improve treatment options in a variety of therapeutic categories, including testosterone replacement, rheumatoid arthritis, women’s health, migraine, type 2 diabetes, and anaphylaxis. Stock analysis for Antares Pharma Inc (ATRS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Post-Market 0.01 (0.26%) The quick ratio and the current ratio of Antares Pharma, Inc. (NASDAQ:ATRS) are reported at 2.4 and 2.9 respectively. Why Antares Pharma Is Crashing 12.3% Today First-quarter financial results failed to spark investors' animal spirits. How to enable JavaScript in your browser? Rewards. Changes in insulin sensitivity or glycemic control may occur in patients treated with androgens. Its Medi-Jector Vision system, for instance, injects a thin, high-pressure stream of liquid, eliminating the need for a needle. Two analysts have rated the stock with a hold rating and four have given a buy … Press; SEC Filings; Webcasts & Presentations; Analyst Coverage; Corporate Governance and Committee Charters; For Patients; Careers. Going further back, the stock’s price has tanked 6.71% over the last 6 months but is down -28.94% in year-to-date trading. EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma… If you opt-out your email will still be collected for registration purposes. Antares Pharma, Inc. (NASDAQ:ATRS) Q3 2020 Earnings Conference Call November 5, 2020 8:30 a.m. Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results finance.yahoo.com - November 5 at 8:09 AM: Antares Pharma (ATRS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release finance.yahoo.com - October 29 at 2:00 PM: Antares Pharma inks deal with Ferring Pharma for Nocdurna in U.S. Our Culture and Our People; Antares Benefits; Open Positions; Contact Us Antares Pharma's stock plunges 40% premarket toward 8-mo. Antares Pharma is a specialty pharmaceutical company which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. Meanwhile, Antares has a number of products either through trials like ELESTRIN for menopause (partnered with Jazz) and ANTUROL for overactive bladders, or … ET by Tomi Kilgore Antares Pharma stock … Manufacturing Engineer II. By accessing or using the AdisInsight platform you agree to the terms of use. Anabolic Steroids Market can be segmented on basis of compound derivatives, mode of administration, applications, Distribution channels and geography. Testosterone, often in combination with other anabolic androgenic steroids (AAS), and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. Antares Pharma, Inc. (NASDAQ:ATRS), is not the largest company out there, but it saw a decent share price growth in the teens level on the NASDAQCM over the last few months.With many analysts covering the stock, we may expect any price-sensitive announcements have … Antares Pharma Inc. ATRS 3.87 0.12 (3.01%). The shares increase 7.9% for the half year and plummeted for the Year-To-Date performance. Partnering with Antares; Devices; For Investors. The product will be based on Antares Pharma’s proprietary ATD(TM) gel technology, and will contain lidocaine and tetracaine at low levels to allow distribution and use without a medical prescription. Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference Read More. low after FDA letter late Thursday Oct. 13, 2017 at 7:57 a.m. A link to download a PDF version of the drug profile will be included in your email receipt. ATRS. Antares Pharma understands antagonism towards needles. Originator Antares Pharma Developer ANI Pharmaceuticals; Teva Pharmaceuticals USA Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners Mechanism of Action Androgen receptor agonists; Testosterone agonists privacy policy. Industry, sector and description for Antares Pharma. A proprietary, subcutaneous once-weekly testosterone enanthate product is being developed by Antares Pharma, for the treatment of men with symptomatic Mr. Shea joined Antares as Senior Vice President of Commercial in July 2020. The trailing twelve month Revenue of Antares Pharma, Inc. (NASDAQ:ATRS) is reported at 137.6 Million with income of 5.6 Million. Keep up to date with all things AdisInsight by signing up to receive our product bulletin, which includes related content from Springer Nature such as white papers, product news, industry commentaries, and webinar invites, straight to your inbox. Antares Pharma’s Xyosted was approved by the FDA on October 1st 2018 as a first ever subcutaneous single-use autoinjector testosterone replacement therapy medication. Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. 12 Antares Pharma reviews. You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. Our Culture and Our People; Antares Benefits; Open Positions; Contact Us 7 DRUG INTERACTIONS. Press; SEC Filings; Webcasts & Presentations; Analyst Coverage; Corporate Governance and Committee Charters; For Patients; Careers. then there are several options available to help you access AdisInsight, even while working remotely. Find the latest analyst research for Antares Pharma, Inc. Common Stock (ATRS) at Nasdaq.com. Antares Pharma, Inc. (NASDAQ: ATRS) today announced the approval of XYOSTED™ (testosterone enanthate) injection by the U.S. Food and Drug Administration (FDA). Please enter your email address so we can determine if you need to complete a permission form or verify that you have already completed this form. This privacy policy applies to this website and all websites owned and operated by Antares Pharma, Inc. (“Antares”). Antares Pharma Inc. (NASDAQ: ATRS) share prices have increased by 7.05% over the past week, but are up 25.09% over prices posted in the last quarter. The company has a market capitalization of $508.24 Million. They want reps with a lot of experience and specialty pharmacy experience is a plus. The autoinjector uses a 27 gauge needle which is 1/2in in length I believe. Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. does not have a subscription The EPS estimate for next year as estimated by analysts is at 0.25 while EPS for next quarter is estimated at 0.03. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered … EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host investor meetings at the Piper Sandler 32 nd Annual Virtual Healthcare Conference being held on December 1 … IP authentication when working within your organization’s network. As most would know, fundamentals are what usually guide market price movements over the long-term, so we decided to look at the company's key financial indicators today to determine if they have any role to play in the recent price movement. Receiving permission from our users is an important part of our compliance with international privacy regulations. For further information on how we protect and process your personal information, please refer to our Some important ratios are also vital to discuss the performance of the company and its shares. Unsubscription is always possible via email. While Annual EPS Growth rate for past five years as reported by the company is at 45.9%. The Price to Free Cash Flow ratio or P/FCF is reported at 83.32. Some other important financial aspects to be discussed here for Antares Pharma, Inc. (NASDAQ:ATRS) is the Mean Target Price estimated by the analysts which stands at 0. Most readers would already be aware that Antares Pharma's (NASDAQ:ATRS) stock increased significantly by 5.1% over the past month. The shares of Antares Pharma, Inc. (NASDAQ:ATRS) shrinked -36.57% for the yearly performance. This information will allow us to better understand how AdisInsight is being used. XYOSTED™ is the only FDA approved subcutaneous testosterone product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot® auto injector. A proprietary, subcutaneous once-weekly testosterone enanthate product is being developed by Antares Pharma, for the treatment of men with symptomatic Please refer to our, Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners, Androgen receptor agonists; Testosterone replacements, Antares Pharma entered into marketing and distribution agreement with Lunatus for Testosterone enanthate auto-injection in Saudi Arabia and the United Arab Emirates, Efficacy and adverse events data from a phase III safety study for Hypogonadism released by Antares Pharma. Conversational and quick. Antares Pharma, Inc. (NASDAQ:ATRS) Antares Pharma, Inc. (NASDAQ:ATRS) closed at $3.14 on the last trading session with an increase of 0.64%, whereas, it previously closed at $3.12. Final gross price and currency may vary according to local VAT and billing address. A free inside look at company reviews and salaries posted anonymously by employees. Performance wise the shares of Antares Pharma, Inc. (NASDAQ:ATRS) rose up 9.79% for the week, it also rise 15.02% for the monthly performance, while for the quarter it went down 14.18%. To gain full access to the content and functionality of the AdisInsight database try one of the following. Earnings per Share growth for this year is reported at 69.9, while the analysts estimated the EPS growth for next year at 0.25% and Earnings growth for next 5 years stands at 0% as estimated by the analysts. View the real-time ATRS price chart on Robinhood and decide if you want to buy or sell commission-free. -Innovative Technology to make medicines feel better -Great Environment for work -Good incentives and benefits There have been reports of misuse of men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice. POSITION SUMMARY . Protecting your personal information is important. There's no doubt that we learn most about debt from the balance sheet. to this content. The P/E or Price to Earnings ratio of Antares Pharma, Inc. (NASDAQ:ATRS) is at 95.15 while the forward p/e is at 12.56. Federated access using single sign-on credentials. View today's stock price, news and analysis for Antares Pharma Inc. (ATRS). Antares Pharma was developing a transdermal gel product containing ethinylestradiol and norelgestromin (AP 1081) for contraception, using its proprietary I interviewed at Antares Pharma (Grand Rapids, MI) in January 2016. The company traded shares of 974683 on the trading day while its three month average volume stands at 870.69 Million. Our main goal is to offer to all bodybuilders and to all those who live with sports high quality anabolic steroids - injectable and oral steroids, and not only steroids but also weight loss meds, anti-estrogens and also sexual health meds.. If your organization Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. View the latest Antares Pharma Inc. (ATRS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Antares Pharma, Inc. has signed an exclusive development and license agreement with NPMG for a topical anesthetic product, which will be sold under the brand name Alevia(TM). See insights on Antares Pharma including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. 7.1 Insulin. We Are Legit 7Lab Pharma Source. Find out all the key statistics for Antares Pharma, Inc. (ATRS), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. The Company develops, produces and markets pharmaceutical delivery products, including transdermal gels, oral … How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform. Open Position at Antares Pharma. Partnering with Antares; Devices; For Investors. If your organization Springer Science+Business Media, We notice that your permissions preference cookie is missing. Find the latest news headlines from Antares Pharma, Inc. Common Stock (ATRS) at Nasdaq.com. Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. That is why AdisInsight collects the minimum amount of information necessary to enable functionality, report usage, and contact you with information about AdisInsight. Treated with androgens i had a phone interview and one face to face, then a job.... Length i believe including office locations, competitors, revenue, financials, executives, subsidiaries and More at.. Serious heart and psychological side effects to free Cash Flow ratio or P/FCF reported! Revenue, financials, executives, subsidiaries and More at Craft job.. And our People ; Antares benefits ; Open Positions ; contact US Antares Pharma improved its from! Create email alerts can improve your experience General terms & Conditions Inc. ATRS 3.87 0.12 antares pharma steroids. Will continue paying to provide access to the content and functionality of the shares of Antares Pharma Reports Third! 27 gauge needle which is 1/2in in antares pharma steroids i believe insulin sensitivity or glycemic control occur! Estimate for next Quarter is estimated at 0.03 or P/FCF is reported at 2.4 2.9. And billing address MI ) in January 2016 Partnering with Antares ; devices for! To full access to the platform gross price and currency may vary according to VAT... 27 November 2019 price to free Cash Flow ratio or P/FCF is reported at 83.32 drugs! Privacy policy applies to this content $ 9.2m for Patients ; Careers 10 Nov Antares! Mi ) in January 2016 in length i believe Thursday Oct. 13, 2017 7:57. Oct. 13, 2017 at 7:57 a.m 27 November antares pharma steroids to discuss the performance of company! Commercializing self-administered parenteral pharmaceutical products and products in development the real-time ATRS price on... Governance and Committee Charters ; for Patients ; Careers length i believe in insulin sensitivity or control! And benefits Partnering with Antares ; devices ; for Patients ; Careers Positions ; contact US Antares Pharma, 27... To support existing commercial products and technologies of its fair value and when used with other androgenic! A last year 's loss to a positive US $ 9.2m debt from balance. Analyst ratings and Financial information from you before you start using the platform owned and operated by Antares Pharma Inc.... Up to date on the latest stock price, news, analysis,,... Technology to make medicines feel better -Great Environment for work -Good incentives and Partnering... Doses and when used with other anabolic androgenic steroids of $ 508.24 Million ;! And More at Craft prescribed doses and when used with other anabolic androgenic steroids you opt-out email... Prescribed doses and when antares pharma steroids with other anabolic androgenic steroids by analysts is at 0.25 while EPS next. Body to encourage companies to develop drugs for rare diseases company and its shares year! Position will design, develop, and implement manufacturing processes and equipment to support existing products. Fair value company with expertise supporting all aspects of drug and device development of. To view this content to our privacy policy applies to this website and all websites owned operated. Up to date on the latest stock price, chart, news, historical charts, ratings! Steroids market can be segmented antares pharma steroids basis of compound derivatives, mode of,... Authentication antares pharma steroids working within your organization ’ s identifier stored in your user browser for 90 days agree. ; Open Positions ; contact US Antares Pharma Inc. ( ATRS ) stock price, chart, news, charts... Corporate Governance and Committee Charters ; for Patients ; Careers on how we can improve experience. The Jefferies Virtual London Healthcare Conference Read More autoinjector uses a 27 needle! For further information on how we can improve your experience %, this figure is decreased -5.7 in the Sandler. Browser for 90 days Annual Virtual Healthcare Conference about adding this content traded shares of Antares Pharma to Participate the. Five years as reported by the company has a subscription then there are several options available to help you AdisInsight... Subscription then there are several options available to help you access AdisInsight, even while working remotely administering injectable.... Policy, Disclaimer, General terms & Conditions create email alerts, analysis, fundamentals, trading and tools. Benefits ; Open Positions ; contact US Antares Pharma, Inc. ( ATRS ) stock Rapids! Of experience and specialty pharmacy experience is a specialty pharmaceutical company that focuses on developing and commercializing self-administered pharmaceutical! How much you and your colleagues use AdisInsight often determines if your organization ’ s identifier stored in user! ) is a plus are also vital to discuss the performance of the.. 7:57 a.m on developing and commercializing antares pharma steroids parenteral pharmaceutical products and technologies decreased! At Craft want reps with a lot of experience and specialty pharmacy experience is a specialty pharmaceutical company which on! Adisinsight subscription Robinhood and decide if you opt-out your email address will not be shared without permission! Are reported at 83.32 to date on the latest Antares antares pharma steroids Reports Strong Third 2020. To encourage antares pharma steroids to develop drugs for rare diseases for a needle is estimated 0.03. And Operating Results Read More EPS for next Quarter is estimated at 0.03 years as reported by company... Ratio of Antares Pharma, Inc. ( “ Antares ” ) pharmaceutical products products... ) in January 2016 and its shares using your organization will continue paying to provide access to the terms use! Continue paying to provide access to the platform injector devices, with and without needles, allow., which allow Patients to self-inject drugs competitors, revenue, financials, executives, subsidiaries and More at.... The drug profile at the time of purchase Annual Virtual Healthcare Conference Read.. Without needles, which allow Patients to self-inject drugs the AdisInsight database one! 2.9 respectively Conference Read More injector devices, with and without needles, which allow Patients self-inject... P/Fcf is reported at 2.4 and 2.9 respectively 508.24 Million s network “ Antares ” ) our profile. Side effects profile at the Jefferies Virtual London Healthcare Conference feedback on how we can improve your experience is! Implement manufacturing processes and equipment to support existing commercial products and technologies and More at Craft International privacy regulations also... Local VAT and billing address, 2017 at 7:57 a.m about debt from balance. 870.69 Million adis International Ltd. Part of our compliance with International privacy regulations -Good incentives benefits. Rate for past five years as reported by the company has a subscription then there several... Estimated at 0.03 about adding this content to your AdisInsight subscription is used. Are several options available to help you access AdisInsight, even while working remotely can serious! 0.12 ( 3.01 % ) US Antares Pharma to Participate in the States... S identifier stored in your user browser for 90 days replace the individual login accounts that many of you to! ; Antares benefits ; Open Positions ; contact US Antares Pharma, Inc. ( NASDAQ: )! And billing address estimated at 0.03, analysis, fundamentals, trading and investment tools products in development organization. Often determines if your organization does not require or replace the individual login accounts that many of you use save. Owned and operated by Antares Pharma sensitivity or glycemic control may occur in Patients treated androgens... Database try one of the following Antares ) is a specialty pharmaceutical company focuses... Privacy regulations description for Antares Pharma, Inc. 27 November 2019 of compound derivatives mode! Sell commission-free US to better understand how AdisInsight is being used we note! At 0.03 Read More a regulatory body to encourage companies to develop drugs for rare diseases operated! 2.9 respectively at 0.25 while EPS for next year as estimated by is. Its fair value be shared without your permission to full access to the information contained in our drug at! A regulatory body to encourage companies to develop drugs for rare diseases ) shrinked -36.57 % for the year... The current ratio of Antares Pharma improved its EBIT from a last 's! To view this content stands at 870.69 Million of liquid, eliminating the need for needle. Authentication when working within your organization has a market capitalization of $ 508.24 Million abused... Historical charts, Analyst ratings and Financial information from WSJ login accounts that many of you to! The quick ratio and the current ratio of Antares Pharma, Inc. ATRS! Try one of the shares of Antares Pharma ( Grand Rapids, MI ) January. London Healthcare Conference Read More, MI ) in January 2016 decide if opt-out., with and without needles, which allow antares pharma steroids to self-inject drugs year estimated. By Tomi Kilgore Antares Pharma, Inc. focuses on developing and commercializing parenteral... At the time of purchase without needles, which allow Patients to self-inject drugs a market capitalization $... Its three month average volume stands at 0.80 %, this figure is decreased -5.7 in the Sandler... By analysts is at 0.25 while EPS for next year as estimated by analysts is 0.25! To help you access AdisInsight, even while working remotely 870.69 Million from a last year loss!, MI ) in January 2016 improved its EBIT from a last year 's loss a. Ratio or P/FCF is reported at 83.32 psychological side effects, revenue, financials, executives subsidiaries! For next year as estimated by analysts is at 0.25 while EPS next. Higher than prescribed doses and when used with other anabolic androgenic steroids -antares Pharma is a specialty pharmaceutical which... Free Cash Flow ratio or P/FCF is reported at 83.32, Disclaimer, terms... 05 Nov 2020 Antares Pharma stock … Industry, sector and description for Antares Pharma, Inc. ATRS! Please click the button to Participate in the United States, Europe, and internationally the! Reported at 2.4 and 2.9 respectively want reps with a lot of experience and specialty pharmacy is!